Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506348 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4NOS3NOS1NOS2 | |
| SCHEMBL620193 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4HTR2A | |
| SCHEMBL620192 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4HTR2A | |
| SCHEMBL5878615 | 0.78 | NOS3 (0.41) | CHRNB2CHRNA4NOS3NOS1NOS2 | |
| SCHEMBL620784 | 0.78 | CHRNB2 (0.64) | CHRNB2CHRNA4HTR2ACHRNB4CHRNA3 | |
| SCHEMBL5878612 | 0.78 | NOS3 (0.41) | CHRNB2CHRNA4NOS3NOS1NOS2 | |
| SCHEMBL620785 | 0.78 | CHRNB2 (0.64) | CHRNB2CHRNA4HTR2ACHRNB4CHRNA3 | |
| SCHEMBL5841809 | 0.77 | AAK1 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL5841799 | 0.77 | AAK1 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL7545942 | 0.75 | CHRNB2 (0.48) | CHRNB2CHRNA4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4240815-B2 | — | — | 2009-03-18 | — | — | JP | claimed |
| JP-2006511482-A | — | — | 2006-04-06 | — | — | JP | claimed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | claimed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1086082-B9 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM SCOTT (US) | 2004-10-28 | — | — | US | claimed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | claimed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | claimed |
| JP-2002518373-A | — | — | 2002-06-25 | — | — | JP | claimed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | claimed |
| EP-1086082-A1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999065876-A1 | ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-12-23 | — | — | WO | claimed |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-04-05 | — | — | US | disclosed |
| US-9782404-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-10-10 | — | — | US | disclosed |
| US-9463190-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-11 | — | — | US | disclosed |
| EP-1086082-A1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1056458-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | Wake Forest University (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999065876-A1 | ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999043322-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | WAKE FOREST UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NOS3 1922/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885NOS3 574/4885 |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB2 9/4885CHRNA4 7/4885NOS3 4563/4885 |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NOS3 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.